Schizophrenia News and Research RSS Feed - Schizophrenia News and Research

Schizophrenia is a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. While significant progress has been made in understanding the disease and developing treatments, there remains a significant unmet medical need. More than 50% of patients switch their medication in a given year due to either poor response or the experience of adverse events.
Brain-related discovery could revolutionize treatment for attention-deficit disorders

Brain-related discovery could revolutionize treatment for attention-deficit disorders

Two Simon Fraser University psychologists have made a brain-related discovery that could revolutionize doctors' perception and treatment of attention-deficit disorders. [More]
Structural changes in hippocampus region improve memory function in children

Structural changes in hippocampus region improve memory function in children

Our ability to store memories improves during childhood, associated with structural changes in the hippocampus and its connections with prefrontal and parietal cortices. [More]

Reduced rheumatoid arthritis risk in schizophrenia linked to underreporting

People with a history of schizophrenia appear to have a lower risk of developing rheumatoid arthritis than the general population, but the association may be due to underreporting, say researchers. [More]
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]
Research may provide insight into identifying, helping children with emotional behavior issues

Research may provide insight into identifying, helping children with emotional behavior issues

Research on children orphaned by HIV/AIDS in South Africa may provide insight on how to identify and help children with emotional behavior issues in other areas of the world, which may have limited access to healthcare and further research that could lead to successful interventions. [More]
Study evaluates co-occurrence of cancers in patients with central nervous system disorders

Study evaluates co-occurrence of cancers in patients with central nervous system disorders

The study evaluated the co-occurrence of cancers in patients with central nervous system disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, autism spectrum disorders, Down's syndrome, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. [More]
TSRI scientists to study effects of pain medication on prenatal brain development

TSRI scientists to study effects of pain medication on prenatal brain development

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $472,500 Cutting Edge Basic Research Award (CEBRA) by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health to study models of the brain development of newborns who have been exposed-and become addicted-to prescription pain medication while still in the womb. [More]

Risk factors for complete, attempted suicide in schizophrenia 'confirmed'

Among individuals with schizophrenia, those earliest in their illness course and those with a history of suicide attempts have the highest suicide-related mortality rates, reveals analysis of the international Ziprasidone Observational Study of Cardiac Outcomes. [More]
Medison Pharma inks agreement with Brainsway for exclusive marketing of Deep TMS system in Israel

Medison Pharma inks agreement with Brainsway for exclusive marketing of Deep TMS system in Israel

Medison Pharma has concluded an agreement with the medical device company Brainsway for exclusive marketing and distribution of the Deep TMS (Transcranial Magnetic Stimulation) system in Israel. [More]

State highlights: State mental hospitals compared to prisons; Johnson & Johnson ruling; Va. hospitals pick new leader

Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent. [More]

Findings confirm importance of brain activity during sleep for memory strength and accuracy

The sense of smell might seem intuitive, almost something you take for granted. But researchers from NYU Langone Medical Center have found that memory of specific odors depends on the ability of the brain to learn, process and recall accurately and effectively during slow-wave sleep — a deep sleep characterized by slow brain waves. [More]

New project reveals mysterious processes of human brain

One of the biggest challenges today is to understand the human brain and we never have been closer to realize it. More than 130 institutes are taking part in one of Europe´s largest research projects, funded with 1.2 billion Euros: The Human Brain Project. [More]
Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. [More]

Viewpoints: 'Pent-up demand' for health care; too early for that White House victory lap; the fight over Medicare advantage

More than seven million people have signed up for insurance on the new federal and state health exchanges, President Obama said this week. Millions more could be added to that total once insurers tally up the people who bought policies directly from them and when those who tried to apply on balky websites are able to complete the process. [More]
Study reveals role of dopamine in hippocampus region of brain

Study reveals role of dopamine in hippocampus region of brain

Bruno Giros, PhD, a researcher at the Douglas Mental Health University Institute and a professor in the Department of Psychiatry at McGill University, has demonstrated, for the first time, the role that dopamine plays in a region of the brain called the hippocampus. [More]

Cognitive dysfunction reflected in schizophrenia healthcare costs

Cognitive dysfunction has direct and indirect effects on healthcare costs in patients with schizophrenia, research suggests. [More]
FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration. [More]

Study sheds light on brain mechanisms that make schizophrenia patients misinterpret what they see

People with schizophrenia often misinterpret what they see and experience in the world. New research provides insight into the brain mechanisms that might be responsible for this misinterpretation. [More]

Researchers generate high-resolution blueprint for how to build human brain

Researchers at the Allen Institute for Brain Science have generated a high-resolution blueprint for how to build a human brain, with a detailed map of where different genes are turned on and off during mid-pregnancy at unprecedented anatomical resolution. [More]

EnVivo Pharmaceuticals changes its name to FORUM Pharmaceuticals

EnVivo Pharmaceuticals, Inc. announced today that the company has changed its name to FORUM Pharmaceuticals Inc. The new name better reflects the company's strong position as a late-stage, purpose-built organization that is focused on conquering challenging brain diseases such as schizophrenia and Alzheimer's disease. [More]